High dose IL-2 in the treatment of metastatic melanoma and metastatic renal cell carcinoma.

被引：0
|
作者：
Woodrum, T [1 ]
机构：
[1] Nebraska Med Ctr, Omaha, NE USA
来源：
ONCOLOGY NURSING FORUM | 2004年 / 31卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
86
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [1] The outcome and toxicity profile of checkpoint inhibitor immunotherapy subsequent to high-dose IL-2 in the treatment of metastatic melanoma and renal cell carcinoma.
    Berg, Stephanie A.
    Clark, Joseph I.
    Henry, Elizabeth
    Wagner, Courtney Regan
    Flanigan, Robert Charles
    Mai, Hanh P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [2] Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma
    Saigal, Christopher S.
    Deibert, Christopher M.
    Lai, Julie
    Schonlau, Matthias
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (03) : 308 - 313
  • [3] The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma
    Hughes, Tasha
    Klairmont, Matthew
    Broucek, Joseph
    Iodice, Gail
    Basu, Sanjib
    Kaufman, Howard L.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (04) : 459 - 465
  • [4] The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma
    Tasha Hughes
    Matthew Klairmont
    Joseph Broucek
    Gail Iodice
    Sanjib Basu
    Howard L. Kaufman
    Cancer Immunology, Immunotherapy, 2015, 64 : 459 - 465
  • [5] High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?
    Muhitch, Jason B.
    Schwaab, Thomas
    IMMUNOTHERAPY, 2014, 6 (09) : 955 - 958
  • [6] A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.
    Buchbinder, Elizabeth Iannotti
    Dutcher, Janice P.
    Perritt, Jessica C.
    Clark, Joseph
    Holtan, Shernan G.
    Kirkwood, John M.
    Curti, Brendan D.
    Lao, Christopher D.
    Kaufman, Howard
    Fishman, Mayer N.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC).
    Gunturi, Anasuya
    Aung, Sandra
    McDermott, David F.
    Buchbinder, Elizabeth Iannotti
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Efficacy of gabapentin on pruritus induced by interleukin-2 (IL-2) treatment in patients with metastatic renal cell carcinoma and melanoma
    Lee, S.
    Rusciano, V.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Novel Management of Pruritus in Patients Treated With IL-2 for Metastatic Renal Cell Carcinoma and Malignant Melanoma
    Lee, Sung Ho
    Baig, Mahadi
    Rusciano, Valerie
    Dutcher, Janice P.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (09) : 1010 - 1013
  • [10] The High-Dose Aldesleukin (HD IL-2) "Select'' Trial in Patients with Metastatic Renal Cell Carcinoma (mRCC)
    McDermott, D.
    Ghebremichael, M.
    Signoretti, S.
    Margolin, K.
    Clark, J.
    Sosman, J.
    Dutcher, J.
    Logan, T.
    Appleman, L.
    Atkins, M.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 903 - 904
12345